Abstract
Gliomas are the most common primary central nervous system tumors occurring in children and adults with neurofibromatosis type 1 (NF1). Over the past decade, discoveries of the molecular basis of low-grade gliomas (LGGs) have led to new approaches for diagnosis and treatments. However, these new understandings have not been fully applied to the management of NF1-associated gliomas. A consensus panel consisting of experts in NF1 and gliomas was convened to review the current molecular knowledge of NF1-associated low-grade "transformed" and high-grade gliomas; insights gained from mouse models of NF1-LGGs; challenges in diagnosing and treating older patients with NF1-associated gliomas; and advances in molecularly targeted treatment and potential immunologic treatment of these tumors. Next steps are recommended to advance the management and outcomes for NF1-associated gliomas.
| Original language | English |
|---|---|
| Pages (from-to) | 773-784 |
| Number of pages | 12 |
| Journal | Neuro-oncology |
| Volume | 22 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 9 2020 |
Keywords
- gliomas
- immunotherapy
- molecular-targeted therapy
- neurofibromatosis type 1
- pilocytic astrocytomas